In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today. The big story around Eli Lilly is the success of its GLP-1 drugs Mounjaro (for diabetes) and Zepbound (for weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results